The Procurement Lens.

R&D

Research and development: clinical research, manufacturing, active ingredients and lab supplies.

At a glance

R&D supply markets

IQVIA R&D bookings
$3.2bn
+15%; book-to-bill 1.2x
OfficialIQVIA Q3 2026 results (8-K) · Oct 2026
Lonza 2026 guide
+11-12%
CDMO capacity tight
OfficialManufacturing Chemist · Oct 2026
China share of India API imports
74%
FY25
Thermo Fisher organic
+6%
Lab demand recovering
R&D supply markets have turned in suppliers' favour: CRO bookings and CDMO growth are strong, and US tariffs and BIOSECURE are reshaping where things are made. Lab supplies and APIs are the exceptions, with soft prices to lock in now.

Subcategories

Across R&D

Exhibit 1Supplier growth across R&D

Latest quarter, year on year

Piramal CDMO+36%Samsung Biologics+18.5%IQVIA R&D bookings+15%Medpace+8.5%Thermo Fisher (organic)+6%Avantor (organic)+5.2%ICON-2.9%
OfficialIQVIA Q3 2026 results (8-K) · Oct-Nov 2026

Exhibit 2US tariff on patented drugs and APIs

By origin

Default100%Onshoring plan20%EU15%UK10%
OfficialJD Supra · Apr 2026

Market pulse

4 Nov 2026
Charles River organic +4.7%

Preclinical demand above 1x for a fourth quarter.

Charles River Q3 2026 results (8-K) →
28 Oct 2026
Avantor returns to growth

Distribution margins down; buyers' market.

Avantor (SEC) →
27 Oct 2026
IQVIA best clinical bookings since 2022

$3.2bn, +15%.

IQVIA Q3 2026 results (8-K) →
26 Oct 2026
WuXi AppTec raises guide ahead of BIOSECURE list

List due 18 Dec.

Fierce Pharma →
29 Sep 2026
US patented drug tariffs apply to all importers

100% default; generics exempt for now.

GHY →

Sources